--- title: "Bausch & Lomb (BLCO) news: offering" url: "https://aibio.space/companies/bausch-lomb/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BLCO offering news: Bausch + Lomb closes €675 million secured notes offering, refinances 2027 term loans. Bausch & Lomb Corp (NYSE: BLCO), United States." --- BLCO Bausch & Lomb Corp NYSE · United States # Bausch & Lomb (BLCO) news BLCO offering news Mergers · 2026-10-01 ## [SpyGlass buys lens maker Advanced Vision Science from Santen for about $13 million](https://aibio.space/news/spyglass-buys-lens-maker-advanced-vision-science-santen-about-13/) The cash deal brings in house the company that makes the intraocular lens used in both of SpyGlass's Phase 3 glaucoma trials. The seller, Santen, gets an exclusive right to sell AVS's Eternity lenses in Japan. ## Latest Bausch & Lomb news 1. 2026-01-02 Debt Financing [Bausch + Lomb closes $2,802,125,000 term loan refinancing](https://aibio.space/news/bausch-lomb-closes-2-802-125-000-term-loan-refinancing/) Bausch + Lomb closed a $2,802,125,000 term loan tranche maturing January 15, 2031, used to refinance its term B loans due 2028 and 2031. The margin on term SOFR loans is 3.75%, but the filing does not say how much of the tranche is new cash. 2. 2025-06-27 Debt Financing [Bausch + Lomb closes €675 million secured notes offering, refinances 2027 term loans](https://aibio.space/news/bausch-lomb-closes-675-million-secured-notes-offering-refinances-2027/) The notes mature January 15, 2031 and pay three-month EURIBOR plus 3.875%. The company also arranged a $2.325 billion term loan and an $800 million revolver, using the proceeds to repay and refinance existing debt. ## Bausch & Lomb at a glance - **Ticker**: BLCO - **Listing**: NYSE - **Country**: United States - **Cash, Sep 30, 2026**: $513.0 million ### Related companies - [BIO-TECHNE](https://aibio.space/companies/bio-techne/) NASDAQ: TECH - [Solventum](https://aibio.space/companies/solventum/) NYSE: SOLV - [Green Planet Bio Engineering Co.](https://aibio.space/companies/green-planet-bio-engineering/) OTC: GPLB - [Freenome](https://aibio.space/companies/freenome/) NASDAQ: FRNM - [Stimcell Energetics](https://aibio.space/companies/stimcell-energetics/) OTC: STME - [Curaleaf Holdings](https://aibio.space/companies/curaleaf/) OTC: CURLF - [Brainsway](https://aibio.space/companies/brainsway/) NASDAQ: BWAY - [NEUROONE MEDICAL TECHNOLOGIES](https://aibio.space/companies/neuroone-medical-technologies/) NASDAQ: NMTC ### Also on NYSE - [Edwards Lifesciences](https://aibio.space/companies/edwards-lifesciences/) EW - [UL Solutions](https://aibio.space/companies/ul-solutions/) ULS - [HAEMONETICS CORP](https://aibio.space/companies/haemonetics/) HAE - [Rafael Holdings](https://aibio.space/companies/rafael/) RFL - [GLOBUS MEDICAL INC](https://aibio.space/companies/globus-medical/) GMED - [Stereotaxis](https://aibio.space/companies/stereotaxis/) STXS ## Bausch & Lomb annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$5.10 billion](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000007/) | [$4.79 billion](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000007/) | | Research and development | [$371.0 million](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000007/) | [$343.0 million](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000007/) | | Net income (loss) | [-$360.0 million](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000007/) | [-$317.0 million](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000007/) | | Cash from operations | [$283.0 million](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000007/) | [$232.0 million](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000007/) | | Cash and equivalents | [$383.0 million](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000111/) | [$305.0 million](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000007/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $513.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Bausch & Lomb Has Bausch & Lomb raised money recently? Our latest story on this, dated Jun 27, 2025: "Bausch + Lomb closes €675 million secured notes offering, refinances 2027 term loans". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bausch-lomb-closes-675-million-secured-notes-offering-refinances-2027/). What is the ticker symbol of Bausch & Lomb? Bausch & Lomb Corp trades under the ticker BLCO on NYSE. Where is Bausch & Lomb listed? Bausch & Lomb Corp is listed on NYSE. Which country or territory is Bausch & Lomb listed under? Our directory records Bausch & Lomb Corp under United States. Does aibio.space cover Bausch & Lomb? aibio.space lists Bausch & Lomb Corp among 2,820 public biotech companies and publishes its news here as stories appear. What was Bausch & Lomb's revenue last year? $5.10 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Bausch & Lomb profitable? Bausch & Lomb Corp reported a net loss of $360.0 million for the fiscal year ended Dec 31, 2025, and generated $283.0 million of cash from operations, per its annual report to the SEC. How much does Bausch & Lomb spend on research and development? $371.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Bausch & Lomb have? $513.0 million in cash at Sep 30, 2026, per its 10-Q. What is the latest Bausch & Lomb (BLCO) stock news? Our latest story on Bausch & Lomb, dated Jan 2, 2026: "Bausch + Lomb closes $2,802,125,000 term loan refinancing". Bausch + Lomb closed a $2,802,125,000 term loan tranche maturing January 15, 2031, used to refinance its term B loans due 2028 and 2031. The margin on term SOFR loans is 3.75%, but the filing does not say how much of the tranche is new cash. [Source](https://aibio.space/news/bausch-lomb-closes-2-802-125-000-term-loan-refinancing/). Does Bausch & Lomb have debt, a term loan or convertible notes? Our latest debt story, dated Jan 2, 2026: "Bausch + Lomb closes $2,802,125,000 term loan refinancing". Bausch + Lomb closed a $2,802,125,000 term loan tranche maturing January 15, 2031, used to refinance its term B loans due 2028 and 2031. The margin on term SOFR loans is 3.75%, but the filing does not say how much of the tranche is new cash. [Source](https://aibio.space/news/bausch-lomb-closes-2-802-125-000-term-loan-refinancing/). Which other companies' news mentions Bausch & Lomb? Bausch & Lomb is named in 1 of our story about other companies, most recently: "SpyGlass buys lens maker Advanced Vision Science from Santen for about $13 million" (Oct 1, 2026). [Source](https://aibio.space/news/spyglass-buys-lens-maker-advanced-vision-science-santen-about-13/). How can I follow Bausch & Lomb (BLCO) news? Press Follow on this page to add Bausch & Lomb to your Following list, or subscribe to the aibio.space newsletter. We have published 3 stories naming Bausch & Lomb so far, in Debt Financing, Mergers. ## Investor discussion: Bausch & Lomb Members talk about Bausch & Lomb (BLCO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:BLCO on TradingView](https://www.tradingview.com/symbols/NYSE-BLCO/). ## Listing details Bausch & Lomb Corp is a public biotech or pharmaceutical company listed on NYSE under the ticker BLCO, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Bausch & Lomb Corp - **Ticker**: BLCO - **Listing**: NYSE - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/bausch-lomb/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Bausch & Lomb (BLCO) news: offering", 2026-10-31, https://aibio.space/companies/bausch-lomb/